Search

Search Constraints

You searched for: Author/Creator Nagano Takuya investigator.

Search Results

1. Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. (20th February 2021)